MicroRNA and cyclooxygenase-2 in breast cancer

Li, Wanjun; Zhang, Zhiwei; Wang, Baiyun; Liang, Na; Zhou, Qier; Long, Songkai

doi:10.1016/j.cca.2021.08.007

Cited by 6 publications

(3 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 The classification of breast cancer into subtypes is important for predicting the response of patients to therapy and finding relevant solutions. 9 The surgery is a promising approach for the treatment of breast cancer. A combination of surgery and adjuvant radiation appears to be effective in improving the survival rate of patients and reducing the chance of recurrence.…”

Section: Introductionmentioning

confidence: 99%

“…Breast cancer is divided into various subtypes, including luminal A, luminal B, HER2 + B2, HER‐2 overexpression and triple‐negative breast cancer, among others 8 . The classification of breast cancer into subtypes is important for predicting the response of patients to therapy and finding relevant solutions 9 . The surgery is a promising approach for the treatment of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Ashrafizadeh

Zarrabi

Bigham

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Breast cancer is the most malignant tumor in women, and there is no absolute cure for it. Although treatment modalities including surgery, chemotherapy, and radiotherapy are utilized for breast cancer, it is still a life‐threatening disease for humans. Nanomedicine has provided a new opportunity in breast cancer treatment, which is the focus of the current study. The nanocarriers deliver chemotherapeutic agents and natural products, both of which increase cytotoxicity against breast tumor cells and prevent the development of drug resistance. The efficacy of gene therapy is boosted by nanoparticles and the delivery of CRISPR/Cas9, Noncoding RNAs, and RNAi, promoting their potential for gene expression regulation. The drug and gene codelivery by nanoparticles can exert a synergistic impact on breast tumors and enhance cellular uptake via endocytosis. Nanostructures are able to induce photothermal and photodynamic therapy for breast tumor ablation via cell death induction. The nanoparticles can provide tumor microenvironment remodeling and repolarization of macrophages for antitumor immunity. The stimuli‐responsive nanocarriers, including pH‐, redox‐, and light‐sensitive, can mediate targeted suppression of breast tumors. Besides, nanoparticles can provide a diagnosis of breast cancer and detect biomarkers. Various kinds of nanoparticles have been employed for breast cancer therapy, including carbon‐, lipid‐, polymeric‐ and metal‐based nanostructures, which are different in terms of biocompatibility and delivery efficiency.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Ashrafizadeh

Zarrabi

Bigham

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…miRNAs as suppressors of gene expression, have the ability to control more than 30% of mRNAs, and are involved in the development, apoptosis, cell proliferation, cell differentiation, and stress response [14]. Through a variety of pathways, the acquisition and loss of miRNA function promote cancer growth [15]. Higher levels of circulating miR-122 are associated with BC metastasis.…”

Section: Introductionmentioning

confidence: 99%

A Novel Necroptosis-Related miRNA Signature for Predicting the Prognosis of Breast Cancer Metastasis

Wang

Jiang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Objective. Necroptosis was recently identified as a form of programmed cell death that plays an essential role in breast cancer metastasis. MicroRNAs (miRNAs) have long been recognized to affect cell death and tumor growth. In this study, we aimed to screen for necroptosis-associated miRNAs that predict breast cancer metastasis. Method. This study used The Cancer Genome Atlas (TCGA) public database to obtain miRNA expression data and associated clinical data from breast cancer patients and then retrieved miRNA data related to necrosis and apoptosis. Next, using Cox regression model analysis (univariate or multivariate) as well as a comparison analysis (differential analysis), a prognostic multi-miRNA molecular marker was established. Finally, prognosis-related miRNAs were utilized to identify target genes, and the functions of the target genes were analyzed for enrichment to investigate the probable mechanisms of the miRNAs. Results. Ten miRNAs were screened through differential analysis to build models: hsa-miR-148a-3p, hsa-miR-223-3p, hsa-miR-331-3p, has-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181c-5p, hsa-miR-181d-5p, hsa-miR-200a-5p, hsa-miR-141-3p, and hsa-miR-425-5p. The multivariate Cox regression model was an independent prognostic factor (univariate Cox regression results: HR = 3.2642 , 95 % CI = 1.5773 − 6.7554 , P = 0.0014 ; multivariate Cox regression results: HR = 3.1578 , 95 % CI = 1.5083 − 6 , P = 0.0023 ). The survival curve of the risk score also revealed that patients with a high risk score had a poor prognosis ( P = 2 e − 04 ). The receiver operating characteristic (ROC) curve showed that the model has a certain prediction ability. Batch survival analysis of the miRNAs in the model was conducted and showed that hsa-miR-331-3p ( P = 0.0182 ) was strongly associated with prognosis. Twenty-three predicted target genes were obtained, and Gene Ontology (GO) enrichment analysis showed that these target genes were strongly enriched in transcriptional initiation and cell membrane trafficking. Conclusion. Our research identified a novel miRNA marker for predicting breast cancer patient prognosis and lays the groundwork for future research on necroptosis-related genes.

show abstract

Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2

Shaker

Shahin

AboulMagd

et al. 2022

Bioorganic Chemistry

View full text Add to dashboard Cite

MicroRNA and cyclooxygenase-2 in breast cancer

Cited by 6 publications

References 128 publications

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

A Novel Necroptosis-Related miRNA Signature for Predicting the Prognosis of Breast Cancer Metastasis

Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2

Contact Info

Product

Resources

About